Safety and Immunogenicity of a Malaria Vaccine
Author Information
Author(s): Roestenberg Meta, Remarque Ed, de Jonge Erik, Hermsen Rob, Blythman Hildur, Leroy Odile, Imoukhuede Egeruan, Jepsen Soren, Ofori-Anyinam Opokua, Faber Bart, Kocken Clemens H. M., Arnold Miranda, Walraven Vanessa, Teelen Karina, Roeffen Will, de Mast Quirijn, Ballou W. Ripley, Cohen Joe, Dubois Marie Claude, Ascarateil Stéphane, van der Ven Andre, Thomas Alan, Sauerwein Robert
Primary Institution: Radboud University Nijmegen Medical Centre
Hypothesis
The study aims to compare the safety and immunogenicity of PfAMA1 vaccine formulated with different adjuvants.
Conclusion
All formulations of the PfAMA1 vaccine were immunogenic and induced functional antibodies, with varying reactogenicity profiles.
Supporting Evidence
- Transient pain was the predominant injection site reaction (80–100%).
- Humoral responses were highest in the AS02 groups.
- All adverse events resolved without serious complications.
- Antibodies showed activity in an in vitro growth inhibition assay up to 80%.
- Six volunteers in the AS02 group and one in the Montanide group were withdrawn due to grade 3 erythema.
Takeaway
The study tested a malaria vaccine and found it to be safe and able to make the body produce antibodies, which can help fight the disease.
Methodology
The study was a phase Ia trial with a dose-escalating design, involving healthy male volunteers who received three immunizations at 4-week intervals.
Potential Biases
Potential bias due to the unblinded nature of the trial for the AS02 adjuvanted groups.
Limitations
The trial's small size and the specific demographic of participants limit the generalizability of the results.
Participant Demographics
The participants were healthy, malaria-naïve male volunteers aged 18 to 45, predominantly Caucasian.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI 0.25 to 1.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website